Carmell Co. (NASDAQ:CTCX – Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 94,200 shares, a decline of 66.8% from the January 31st total of 284,100 shares. Based on an average daily volume of 6,440,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.6% of the company’s shares are short sold.
Hedge Funds Weigh In On Carmell
An institutional investor recently bought a new position in Carmell stock. Antara Capital LP acquired a new stake in Carmell Co. (NASDAQ:CTCX – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 100,000 shares of the company’s stock, valued at approximately $28,000. Carmell makes up approximately 0.0% of Antara Capital LP’s investment portfolio, making the stock its 10th largest holding. Antara Capital LP owned approximately 0.48% of Carmell as of its most recent SEC filing. Institutional investors own 24.22% of the company’s stock.
Carmell Stock Performance
Shares of NASDAQ CTCX traded down $0.01 during midday trading on Friday, hitting $0.24. The stock had a trading volume of 214,907 shares, compared to its average volume of 8,762,678. Carmell has a 1-year low of $0.20 and a 1-year high of $3.35. The company has a fifty day moving average price of $0.37 and a 200 day moving average price of $0.40.
Carmell Company Profile
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.
Further Reading
- Five stocks we like better than Carmell
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- What Investors Need to Know to Beat the Market
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- How to Invest in Biotech Stocks
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.
